|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200062681 |
|
最近更新日期: Date of Last Refreshed on: |
2022-08-15 18:21:31 |
|
注册时间: Date of Registration: |
2022-08-15 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
脊髓电刺激装置植入治疗糖尿病相关下肢并发症的有效性和安全性的多中心临床研究 |
|
Public title: |
A multicenter clinical study on the efficacy and safety of spinal cord electrical stimulation device implantation in the treatment of lower limb complications associated with diabetes |
|
注册题目简写: |
脊髓电刺激治疗糖尿病足 |
|
English Acronym: |
Treatment of diabetes foot with spinal cord electrical stimulation |
|
研究课题的正式科学名称: |
脊髓电刺激装置植入治疗糖尿病相关下肢并发症的有效性和安全性的多中心临床研究 |
|
Scientific title: |
A multicenter clinical study on the efficacy and safety of spinal cord electrical stimulation device implantation in the treatment of lower limb complications associated with diabetes |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王毅 |
研究负责人: |
王毅 |
|
Applicant: |
wangyi |
Study leader: |
wangyi |
|
申请注册联系人电话: Applicant telephone: |
13920881956 |
研究负责人电话:
Study leader's |
13920881956 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sinuosiwo@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
sinuosiwo@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津医科大学总医院 |
研究负责人通讯地址: |
天津医科大学总医院 |
|
Applicant address: |
Tianjin Medical University General Hospital |
Study leader's address: |
Tianjin Medical University General Hospital |
|
申请注册联系人邮政编码: Applicant postcode: |
300052 |
研究负责人邮政编码: Study leader's postcode: |
300052 |
|
申请人所在单位: |
天津医科大学总医院 |
||
|
Applicant's institution: |
Tianjin Medical University General Hospital |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB2021-KY-255 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津医科大学总医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of General Hospital of Tianjin Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-26 00:00:00 | ||
|
伦理委员会联系人: |
金东来 |
||
|
Contact Name of the ethic committee: |
Donglai Jin |
||
|
伦理委员会联系地址: |
天津市和平区鞍山道154号 |
||
|
Contact Address of the ethic committee: |
No.154 Anshan Road,Tianjin |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
天津医科大学总医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Medical University General Hospital |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市和平区鞍山道154号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No.154 Anshan Road,Tianjin |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
天津医科大学总医院临床医学研究项目 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Clinical medical research project of Tianjin Medical University General Hospital |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
糖尿病 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
diabetes mellitus |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
从总体目标来看,本课题拟验证脊髓电刺激(SCS)对改善糖尿病相关下肢并发症患者的下肢皮温、疼痛等临床症状,促进下肢神经-血管的修复、溃疡的愈合以及降低截肢的比例等方面的作用,具有较大的临床应用价值和社会意义,将有可能为进一步做好糖尿病下肢相关并发症治疗的行业标准或专家共识的制定提供参考。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
In terms of the overall goal, this topic intends to verify the role of spinal cord electrical stimulation (SCS) in improving the clinical symptoms of lower limb skin temperature and pain in patients with lower limb complications related to diabetes, promoting the repair of lower limb nerves and vessels, healing of ulcers, and reducing the proportion of amputations, which has great clinical application value and social significance, It will be possible to provide reference for further developing industry standards or expert consensus for the treatment of lower limb related complications of diabetes. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
受试者入选标准: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Subject selection criteria: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
排除标准: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-01 00:00:00至 To 2026-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-08-01 00:00:00 至 To 2026-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
为病例治疗前后对比 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Comparison of cases before and after treatment |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
网络平台,2026.12.31,http://www.tjmugh.com.cn/index_yg.shtml |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
website,2026.12.31,http://www.tjmugh.com.cn/index_yg.shtml |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |